TY - JOUR
T1 - The RANTES -403G > A promoter polymorphism in Korean men
T2 - Association with serum RANTES concentration and coronary artery disease
AU - Jang, Yangsoo
AU - Chae, Jey Sook
AU - Hyun, Yae Jung
AU - Koh, Soo Jeong
AU - Kim, Ji Young
AU - Ko, Min Ji
AU - Rim, Se Joong
AU - Shin, Hyun Joon
AU - Ordovas, Jose M.
AU - Lee, Jong Ho
PY - 2007/10
Y1 - 2007/10
N2 - In the present study we investigated the association of the RANTES (regulated upon activation, normal T-cell expressed and secreted) -28C > G and -403G > A promoter polymorphisms with the concentration of serum RANTES and CAD (coronary artery disease) in Korean men. We included 553 male CAD patients with (n = 176) or without (n = 377) Type 2 diabetes, aged 40-65 years with previous myocardial infarction (∼ 50 %) or angiographically confirmed CAD (∼ 50 %), and 416 aged-matched healthy male controls. The main outcome measures were the OR (odds ratio) of CAD risk and the serum RANTES concentration evaluated by sandwich ELISA. Although the RANTES -28C > G genotype had no significant association with CAD risk, the presence of the minor allele of the RANTES -403G > A single nucleotide polymorphism was associated with a lower risk of CAD {OR 0.70 [95% CI (confidence interval) 0.54-0.92], P = 0.011} after adjusting for age, BMI (body mass index), cigarette smoking and alcohol consumption. Serum RANTES concentrations were significantly associated with the -403G > A genotype in controls (G/G: 44.7 ± 3.3 ng/ml, G/A: 36.5 ± 2.0 ng/ml, A/A: 28.7 ± 2.5 ng/ml; P < 0.001), non-diabetic CAD patients (G/G: 50.9 ± 3.0 ng/ml, G/A: 42.2 ± 2.6 ng/ml, A/A: 41.3 ± 4.4 ng/ml; P < 0.05) and diabetic CAD patients (G/G: 58.5 ± 3.5 ng/ml, G/A: 49.6 ± 4.1 ng/ml, A/A: 42.2 ± 4.3 ng/ml; P < 0.05); however, such associations were not observed in the subgroup of CAD patients taking lipid-lowering medication. Moreover, serum RANTES was positively correlated with C-reactive protein (r = 0.289, P < 0.001) and platelet counts (r = 0.253, P < 0.001). The results of the present study demonstrate that the RANTES -403A allele is associated with lower serum RANTES concentrations and consequently with reduced CAD risk.
AB - In the present study we investigated the association of the RANTES (regulated upon activation, normal T-cell expressed and secreted) -28C > G and -403G > A promoter polymorphisms with the concentration of serum RANTES and CAD (coronary artery disease) in Korean men. We included 553 male CAD patients with (n = 176) or without (n = 377) Type 2 diabetes, aged 40-65 years with previous myocardial infarction (∼ 50 %) or angiographically confirmed CAD (∼ 50 %), and 416 aged-matched healthy male controls. The main outcome measures were the OR (odds ratio) of CAD risk and the serum RANTES concentration evaluated by sandwich ELISA. Although the RANTES -28C > G genotype had no significant association with CAD risk, the presence of the minor allele of the RANTES -403G > A single nucleotide polymorphism was associated with a lower risk of CAD {OR 0.70 [95% CI (confidence interval) 0.54-0.92], P = 0.011} after adjusting for age, BMI (body mass index), cigarette smoking and alcohol consumption. Serum RANTES concentrations were significantly associated with the -403G > A genotype in controls (G/G: 44.7 ± 3.3 ng/ml, G/A: 36.5 ± 2.0 ng/ml, A/A: 28.7 ± 2.5 ng/ml; P < 0.001), non-diabetic CAD patients (G/G: 50.9 ± 3.0 ng/ml, G/A: 42.2 ± 2.6 ng/ml, A/A: 41.3 ± 4.4 ng/ml; P < 0.05) and diabetic CAD patients (G/G: 58.5 ± 3.5 ng/ml, G/A: 49.6 ± 4.1 ng/ml, A/A: 42.2 ± 4.3 ng/ml; P < 0.05); however, such associations were not observed in the subgroup of CAD patients taking lipid-lowering medication. Moreover, serum RANTES was positively correlated with C-reactive protein (r = 0.289, P < 0.001) and platelet counts (r = 0.253, P < 0.001). The results of the present study demonstrate that the RANTES -403A allele is associated with lower serum RANTES concentrations and consequently with reduced CAD risk.
UR - http://www.scopus.com/inward/record.url?scp=34648835376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34648835376&partnerID=8YFLogxK
U2 - 10.1042/CS20070014
DO - 10.1042/CS20070014
M3 - Article
C2 - 17504241
AN - SCOPUS:34648835376
SN - 0143-5221
VL - 113
SP - 349
EP - 356
JO - Clinical Science
JF - Clinical Science
IS - 7-8
ER -